Trial Profile
Effect of DAIKENCHUTO (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Female Patients With Functional Constipation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Mar 2017
Price :
$35
*
At a glance
- Drugs TU 100 (Primary)
- Indications Constipation
- Focus Pharmacodynamics
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2012 New trial record